NEW FDA DRUG APPROVALS
|
|
- Cornelius Edwards
- 5 years ago
- Views:
Transcription
1 NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018
2 Disclosures We have nothing to disclose.
3 Objectives Review the Food and Drug Administration's (FDA) responsibilities and approval process Recognize common components of generic drug names Review diseases processes and new agents approved to treat hematologic malignancies
4 U.S. Food and Drug Administration (FDA)
5 FDA Mission Responsible for ensuring the safety, efficacy and security of Drugs and biological products Medical devices Food supply, cosmetics, radiation products Responsible for regulating tobacco products Help the public get the accurate, science-based information FDA does not take into account cost or payment FDA does not regulate the practice of medicine
6 FDA Accounts for 20 cents of every dollar spent by Americans Over 17,000 prescription drug products Approximately 320 FDA-licensed biologics products cm htm
7 Oncology Therapeutics Center for Drug Evaluation and Research Office of Hematology and Oncology Products (OHOP) Oncology Center of Excellence Severe and lifethreatening diseases Large public interest, active advocacy groups Oncology therapeutics are unique! 40% of drugs being developed Large public interest, active advocacy groups Different risk tolerance for side effects 50% of breakthrough therapies
8 FDA Drug Review Process Traditional approval (goal of 10 months) Requires substantial evidence of safety and efficacy Well-controlled clinical trials Based on prolongation of life or a better life, or surrogate As safe and effective as existing therapies (non-inferiority design) eatures/ucm htm
9 FDA Expedited Programs Fast Track Breakthrough Therapy Accelerated Approval Priority Review Quicker access to life-saving therapies Early evidence suggests substantial improvement over current therapies Strong early surrogate or intermediate endpoints Late evidence suggests substantial improvement over current therapies Actions to expedite development and review Intensive guidance on drug development *Fast Track features Approval based on surrogate endpoint that is likely to predict meaningful benefit over existing therapies Shorter goal of action and review time (6 months) For serious conditions and fill an unmet medical need. Must show potential advantage over available therapy For serious conditions and preliminary evidence indicates substantial improvement over available therapies ~ 50% requests have been in oncology ~1/3 have been granted For serious conditions and demonstrates an effect on surrogate endpoint that is likely to predict benefit or clinical endpoint that can be measured earlier For serious conditions and demonstrates significant improvements (clinical endpoint or surrogate) compared to standard
10 Orphan Drug Designation Special status granted to a drug or biological product that treats a rare disease or condition Both the drug and disease must meet certain criteria Provides development incentives Over 3,500 orphan drug designation issued since 1983 Over 600+ orphan drug indications approved 60% of Breakthrough Therapies approved are indicated for rare diseases
11 Common Components of Generic Drug Names
12 Monoclonal Antibodies = mab Origin of monoclonal antibodies: Mo = mouse (blinatumomab) Xi = chimeric: cross of mouse and human (rituximab) Zu = humanized (alemtuzumab) U = fully human (daratumumab) Target helps guide knowledge of common side effects: Tu = target is on the tumor cell: blinatumomab Ci = target is circulatory or blood vessels: bevacizumab Li or I = immunomodulator: pomalidomide
13 Small Molecules - Nibs Many are oral agents Adherence Drug/drug interactions and drug/food interactions Patient education Activity is intracellular Nibs and tinibs Tyrosine kinase inhibitors: block enzymes (BCR-ABL in CML) found on cancer cells Examples: imatinib, dasatinib, ibrutinib, bosutinib
14 New FDA Approved Agents
15 Acute Lymphoblastic Leukemia (ALL) Rapidly progressing, arising from lymphoid line of blood cells Most common pediatric malignancy 85% of children with ALL survive 5 years or longer 15-20% of children with ALL relapse 50% chance of cure if obtain second remission 20-30% chance of cure if relapse during therapy Overall survival for adults with ALL is poor (30-40%) Most common presenting symptoms are palpable liver, palpable spleen, pallor, fever, and bruising
16 Tisagenlecleucel (Kymriah) Approved August 2017 (priority review, regular approval) Mechanism: CD19 directed genetically modified autologous T-cell immunotherapy Indication: patients up to age 25 years with relapsed and/or refractor B-cell precursor ALL that is refractory or in a second or late relapse Genetically modified autologous T-cells to target CD19+ B cells (normal and malignant) Tocilizumab approved to treat patient 2 years or older with CRS occurring with CAR T therapy
17
18 Tisagenlecleucel (Kymriah ) Key point: only available through the Kymriah REMS program Dosing: Lymphodepleting fludarabine and cyclophosphamide 2-14 days prior to CAR T cells Patients 50 kg or less = x 10 6 CAR T-cells/kg Patients above 50 kg = x 10 8 total CAR T-cells Premedicate with acetaminophen and an H1-antihistamine
19 Tisagenlecleucel (Kymriah ) Common AE: cytokine release syndrome (CRS), hypogammoglobulinemia, infection, pyrexia, decreased appetite, headache, encephalopathy, hypotension, bleeding, tachycardia, n/v/d, hypoxia, fatigue, acute kidney injury Warnings and precautions CRS Neurologic toxicities Administration: autologous and intravenous use only Confirm patient identity Confirm availability of tocilizumab prior to infusion Infuse ml per minute
20 Inotuzumab Ozogamicin (Besponsa ) Approved August 2017 (orphan drug, breakthrough therapy, priority review) Mechanism: anti-cd22 monoclonal antibody-drug conjugate with calicheamicin Indication: adults with relapsed or refractory B-cell precursor ALL Dosing: Administered on Day 1, 8, and 15 of each 3-4 week cycle Premedicate with corticosteroid, antipyretic and antihistamine
21 Inotuzumab Ozogamicin (Besponsa ) Administration: intravenous Monitor for at least 1 hour after end of infusion Common AE: myelosuppression, thrombocytopenia, neutropenia, infection, anemia, abdominal pain, hyperbilirubinemia Warnings and precautions Hepatotoxicity Myelosuppression Infusion reactions QT interval prolongation
22 Blinatumomab (Blincyto ) Approved July 2017 expanded indication to Ph+ ALL Mechanism: CD19 directed CD3 T-cell engager that results in lysis of CD19+ cells Indication: relapsed or refractory B-cell precursor ALL in adults and children
23 Blinatumomab (Blincyto ) Dosing: Premedicate with dexamethasone Common AE: infections, fever, headache, infusion reactions, febrile neutropenia, myelosuppression
24 Blinatumomab (Blincyto ) Warnings and Precautions Cytokine release syndrome (CRS) Neurologic toxicities Key points Hospitalization recommended for the first 9 days of the first cycle and first 2 days of second cycle Administration Continuous IV infusion at a constant rate using an infusion pump over 24 hours, 48 hours, or 7 days Do not flush infusion line, flushing can result in excess dosage
25 Chronic GVHD Serious complication of allogeneic hematopoietic stem cell transplantation Affects 30-70% of patients Donor immune cells (the graft) recognize the recipient (host) as foreign and mount an immunologic attack Few effective options after treatment with corticosteroids, no standard of care for second-line treatment
26 Ibrutinib (Imbruvica ) Approved August 2017 (breakthrough therapy) expanded indication Mechanism: small molecule inhibitor of Bruton s tyrosine kinase (BTK) in B cells Indication: adult patients with chronic GVHD after failure of one or more lines of systemic therapy Dosing: 420 mg taken orally once daily Common AE: fatigue, bruising, diarrhea, thrombocytopenia, stomatitis, muscle spasms, nausea, hemorrhage, anemia, pneumonia
27 Ibrutinib (Imbruvica ) Administration Three 140 mg capsules once daily Capsules should be taken with water Do not break, open, or chew the capsules
28 Follicular Lymphoma Most common indolent non-hodgkin lymphomas Arises from germinal center B cells Median age of diagnosis 65 years Mostly asymptomatic other than lymph node enlargement Most patients will experience serial relapse, prognosis poor for early relapse after treatment
29 Copanlisib (Aliqopa ) Approved September 2017 (orphan drug, fast track, priority review, accelerated approval) Mechanism: PI3K-α and δ inhibitor Indication: adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies Dosing: 1-hr IV infusion on Days 1, 8, and 15 of a 28-day treatment cycle (3 weeks on, 1 week off) Common AE: hyperglycemia, diarrhea, fatigue, hypertension, leukopenia, neutropenia
30 Rituximab SQ with Hyaluronidase (Rituxan Hycela ) Approved June 2017 (regular approval) Mechanism: anti-cd20 monoclonal antibody, hyaluronidase cleaves hyaluronan Indications: newly diagnosed DLBCL with CHOP, CLL with FC, FL as a single agent or with chemotherapy Key Point: patients must have had at least one prior rituximab IV infusion Dosing: FL/DLBCL: 11.7 ml over 5 minutes CLL: 13.4 ml over 7 min Premedicate with acetaminophen and antihistamine and potentially glucocorticoid
31 Rituximab SQ with Hyaluronidase (Rituxan Hycela ) Common AE: infections, neutropenia, nausea, cough, and fatigue, thrombocytopenia, pyrexia, vomiting, injection site erythema Warnings and precautions Hypersensitivity and local administration reactions Hepatitis B reactivation Tumor lysis syndrome Infections Administration: subcutaneous injection in the abdomen Never inject into areas of compromised skin or moles and scars Observe 15 minutes following administration
32 Hyaluronidase Hyaluronan (hyaluronic acid) is a major component of the extracellular matrix of subcutaneous tissue and creates a barrier to interstitial fluid flow. Hyaluronidase human cleaves hyaluronan through depolyymerization Depolymerization of hyaluronan increases the permeability of tissue, increases the absorption rate into the systemic circulation. Reduces administration time from 3-4 hours to 5-7 minutes!
33 Lymphoma Cancer that begins in the cells of the lymph system Can occur in both children and adults Two main types: Hodgkin lymphoma: classic (most common) Non-Hodgkin lymphoma: many different types Diffuse large B-cell Follicular Mantle cell Mycosis fungoides
34 Acalabrutinib (Calquence ) Approved in October 2017 (accelerated approval) Mechanism: small-molecule inhibitor of Bruton's tyrosine kinase (BTK) Indication: mantle cell lymphoma who had received at least one prior therapy Dosing: 100 mg orally twice daily, approximately every 12 hours Common AE: anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia and bruising
35 Axicabtagene ciloleucel (Yescarta ) Approved October 2017 (regular approval) Mechanism: CD19 directed genetically modified autologous chimeric antigen receptor (CAR) T-cell immunotherapy Genetically modified autologous T-cells to target CD19+ B- cells (normal and malignant) Indication: treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy Dosing: 2 x 10 6 CAR-positive viable T-cells per kg
36 Axicabtagene ciloleucel (Yescarta ) Key point: available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) Common AE: fever, hypotension, encephalopathy, tachycardia, fatigue, headache, decreased appetite, chills, diarrhea, febrile neutropenia, nausea/vomiting, hypoxia, tremor, dizziness, and cardiac arrhythmias Warnings and precautions: Cytokine release syndrome (CRS) Neurologic toxicities
37 Brentuximab Vedotin (Adcetris ) Approved November 2017 (regular approval) Mechanism: CD30 directed antibody-drug conjugate Indication: treatment of adult patients with primary cutaneous anaplastic large cell lymphoma or CD30 expressing mycosis fungoides who have received prior systemic therapy Dosing: 1.8 mg/kg up to a maximum of 180 mg as an intravenous infusion over 30 minutes every 3 weeks Common AE: anemia, nausea/vomiting, neuropathy, fatigue, neutropenia
38 Pembrolizumab (Keytruda ) Approved March 2017 (accelerated approval) Mechanism: programmed death receptor-1 (PD-1) blocking antibody Indication: treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma, or those who have relapsed after three or more prior lines of therapy Dosing: 200 mg every 3 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics
39 Pembrolizumab (Keytruda ) Common AE: fatigue, pruritus, diarrhea, decreased appetite, rash, pyrexia, cough, dyspnea, musculoskeletal pain, constipation, and nausea Warnings: Immune mediated inflammation Infusion reactions
40 Chronic Myelogenous Leukemia (CML) Occurs most often during or after middle age, rarely in children The bone marrow produces too many white blood cells Common symptoms: fever, night sweats and fatigue Most patients have a gene mutation called Philadelphia chromosome
41
42 Dasatinib (Sprycel ) Approved in November 2017 (regular approval) Mechanism: tyrosine kinase inhibitor for BCR-ABL, SRC family, c-kit, EPHA2, and PDGFRβ Indication: pediatric patients with Philadelphia chromosome positive CML in chronic phase Dosing: by body weight, re-evaluate every 3 months Common AE: in patients with newly diagnosed chronic phase CML included myelosuppression, fluid retention, diarrhea, headache, musculoskeletal pain, rash and fatigue
43 Multiple Myeloma A hematologic malignancy that originates in the plasma cells Myeloma cells produce abnormal antibodies, M proteins Ultimately overproduction of M proteins lead to bone and kidney damage Genetic factors may influence one s likelihood of developing multiple myeloma Prognosis varies and many new treatments have recently been approved
44 Multiple Myeloma
45 Lenalidomide (Revlimid ) Approved February 2017 (expanded indication) Mechanism: immunomodulatory, antiangiogenic, and antineoplastic properties. Inhibits production and induces apoptosis of certain hematopoietic tumor cells Indication: maintenance therapy for multiple myeloma post autologous stem cell transplant Dosing: 10mg PO daily administered day 1-28 of a 28 day cycle for maintenance post HCT
46 Lenalidomide (Revlimid ) Common AE: diarrhea, fatigue, anemia, constipation, neutropenia, peripheral edema, insomnia Warnings: Fetal toxicity Thrombosis risk Hematologic toxicity
47 Acute Myelogenous Leukemia (AML) Most common acute leukemia in adults The bone marrow produces abnormal myeloblasts Risk factors: smoking, radiation exposure and previous chemotherapy exposure There are multiple subtypes of AML Common presenting symptoms are easy bruising, bleeding, fever and fatigue
48 Midostaurin (Rydapt ) Approved April 2017 (breakthrough designation) Mechanism: small molecule that inhibits multiple receptor tyrosine kinases Indication: newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive in combination with standard cytarabine and daunorubicin induction and standard consolidation with cytarabine Dosing: 50mg BID with food on days 8-21 of induction and consolidation Common AE: febrile neutropenia, nausea/vomiting, mucositis, headache, petechiae, musculoskeletal pain, epistaxis, infection, and hyperglycemia
49 Enasidenib (Idhifa ) Approved August 2017 (regular approval) Mechanism: small molecule isocitrate dehydrogenase-2 inhibitor Indication: treatment of adult patients with relapsed or refractory AML with an IDH2 mutation Dosing: 100 mg PO daily Common AE: nausea, vomiting, diarrhea, elevated bilirubin, and decreased appetite
50 Liposomal Cytarabine and Daunorubicin (Vyxeos ) Approved August 2017 (regular approval) Mechanism: daunorubicin has antimitotic and cytotoxic activity, cytarabine is a cell cycle phase-specific antineoplastic agent Indication: treatment of adults with newly-diagnosed therapyrelated AML or AML with myelodysplasia-related changes Dosing: daunorubicin 44mg/m2 and cytarabine 100 mg/m2 on days 1, 3 and 5 Common AE: hemorrhagic events, febrile neutropenia, rash, edema, nausea/vomiting/diarrhea, mucositis, constipation, musculoskeletal pain, fatigue, abdominal pain, dyspnea, headache, cough, decreased appetite, arrhythmia, pneumonia, and bacteremia
51 Gemtuzumab Ozogamicin (Mylotarg ) Approved September 2017 (regular approval) Mechanism: CD33 directed monoclonal antibody-drug conjugate Indication: the treatment of newly-diagnosed CD33 positive acute myeloid leukemia (AML) in adults and for treatment of relapsed or refractory CD33 positive AML in adults and in pediatric patients 2 years and older. Dosing: 3 mg/m2 for newly diagnosed AML in combination with daunorubicin and cytarabine on days 1, 4 and 7
52 Gemtuzumab Ozogamicin (Mylotarg ) Common AE: hemorrhage, infection, fever, nausea, vomiting, constipation, headache, increased AST, increased ALT, rash, and mucositis Warning: Severe or fatal hepatic veno-occlusive disease Infusion related reactions
53 Bosutinib (Bosulif ) Approved in December 2017 (accelerated approval) Mechanism: a tyrosine kinase inhibitor. Bosutinib inhibits BCR-ABL kinase that promotes CML Indication: newly diagnosed Philadelphia chromosome positive CML in chronic phase Dosing: Daily dosing of 400 mg recommended to be taken with food Common AE: diarrhea, nausea/vomiting, thrombocytopenia, abdominal pain, rash, anemia, pyrexia, and fatigue
54 Potential Future Treatment Options Crenolanib: a tyrosine kinase inhibitor, potent inhibitor of FLT3-ITD Quizartinib: a tyrosine kinase inhibitor, a FLT3-ITD inhibitor showing results as a monotherapy Gliteritinib: a tyrosine kinase inhibitor, for treatment in adults with FLT3 positive relapsed/refractory AML Ivosidenib: small molecule inhibitor for high-risk relapsed or refractory AML patients with an IDH1 mutation
NEW FDA DRUG APPROVALS
NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018 Disclosures We have nothing
More informationNew Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents
New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA Associate Professor, Hematology/Medical Oncology and Pharmacology
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More information(212) (347)
EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationHighlights from the 2017 Annual Meeting of the American Society of Hematology
Latest NEWS IN BLOOD CANCER RESEARCH Highlights from the 2017 Annual Meeting of the American Society of Hematology CancerCare Connect Booklet Series www.cancercare.org The CancerCare Connect Booklet Series
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationHematologic Malignancies: Top Ten Advances Impacting Clinical Practice
Hematologic Malignancies: Top Ten Advances Impacting Clinical Practice Adam D. Cohen, MD Abramson Cancer Center University of Pennsylvania June 14, 2018 Please note that some of the studies reported in
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationCurrent Strategies for Relapsed/Refractory ALL in AYAs and Adults: Where We Are Now
Current Strategies for Relapsed/Refractory ALL in AYAs and Adults: Where We Are Now Eunice S. Wang, MD Roswell Park Cancer Institute Buffalo, New York, United States Relapsed ALL Carries a Poor Prognosis
More informationRECOGNITION AND MANAGEMENT OF TOXICITIES OF ORAL THERAPEUTICS IN HEMATOLOGIC MALIGNANCIES
RECOGNITION AND MANAGEMENT OF TOXICITIES OF ORAL THERAPEUTICS IN HEMATOLOGIC MALIGNANCIES Michelle Wright Mast, FNP-BC Hematology Oncology of Indiana, PC No disclosures Objectives Increase knowledge of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationNew Drug Talk August 4, 2018
New Drug Update Tatjana Grgic, PharmD BCOP CPP Clinical Pharmacist Practitioner University of North Carolina Medical Center August 4, 2018 Disclosures I have nothing to disclose related to the content
More informationUpdates in Hematology
Updates in Hematology Disclosure Received honoraria on Speaker s Bureau for Pfizer and Takeda Oncology Received honoraria for Advisory Board of Pfizer and Lilly Manpreet Chahal, PharmD, PhD Oncology Pharmacist,
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Monoclonal Antibodies Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationmidostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age.
midostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age. perc deliberated on the toxicity profile of midostaurin and noted that
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationAn Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib)
An Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib) IMBRUVICA (ibrutinib) is a meaningful and important treatment option for patients with chronic lymphocytic
More informationBLOOD AND LYMPH CANCERS
BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber
More informationNew Immunotherapies Prior to Stem Cell Transplant
New Immunotherapies Prior to Stem Cell Transplant Jill K. Leslie, PharmD, BCPS, BCOP Clinical Pharmacy Specialist: Bone marrow transplant and Hematology Services Franciscan Health-Indianapolis Indiana
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More information-- Manufacturing Success Rate of 99 Percent in ZUMA-1 Pivotal Trial with a Median 17 Day Turnaround Time --
Kite s Yescarta (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of
More informationMYLOTARG (gemtuzumab ozogamicin)
MYLOTARG (gemtuzumab ozogamicin) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationFACULTY TRAINING TRANSCRIPT
FACULTY TRAINING TRANSCRIPT PROGRAM CURRICULUM REVIEWED BY: B. DOUGLAS SMITH, MD Professor of Oncology Johns Hopkins University, School of Medicine Baltimore, MD JONATHAN WEBSTER, MD Instructor of Oncology
More informationAdvances in the Treatment of Hematologic Malignancies. Disclosures
Advances in the Treatment of Hematologic Malignancies A Review of Newly Approved Drugs Katherine Shah, PharmD, BCOP Clinical Pharmacy Specialist, Hematology/Oncology Emory University Hospital / Winship
More informationUnderstanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationEngineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL
Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL Diana Schreier, Pharm.D., M.B.A. Pharmacy Grand Rounds October 17, 2017 2017 MFMER
More informationoffers the possibility of a longer life 1 BLINCYTO A guide for patients and caregivers
In a study of 405 adults with Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, 271 were treated with BLINCYTO and 134 with chemotherapy. The adults
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationIMMUNE EFFECTOR CELLS: CAR T AND OTHER CYTOTOXIC EFFECTOR CELLS OF THE IMMUNE SYSTEM
IMMUNE EFFECTOR CELLS: CAR T AND OTHER CYTOTOXIC EFFECTOR CELLS OF THE IMMUNE SYSTEM Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationTKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients. Moustafa Sameer Hematology Medical Advsior,Novartis oncology
TKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients Moustafa Sameer Hematology Medical Advsior,Novartis oncology Introduction In people with chronic myeloid leukemia, A
More informationintolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra*
What s New Medical Pharmaceutical Policy March 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated policy Remicade (infliximab), Inflectra (infliximab-dyyb)
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationWhat should I ask my treatment team?
TREATMENT TRANSFORMED Child portrayed is not a real KYMRIAH patient. DISCUSSION GUIDE What should I ask my treatment team? Making treatment decisions for relapsed or refractory cancer can be hard. Asking
More informationImbruvica. Imbruvica (ibrutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.41 Subject: Imbruvica Page: 1 of 5 Last Review Date: June 22, 2017 Imbruvica Description Imbruvica
More informationI fattori di rischio per infezioni in ematologia: tra vecchie e nuove classificazioni Livio Pagano
I fattori di rischio per infezioni in ematologia: tra vecchie e nuove classificazioni Livio Pagano Istituto di Ematologia Roma Invited Speaker Consultant Research grants New chemotherapic agents already
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. ADCETRIS (brentuximab
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationREMS Program Live Training FOR TRAINING PURPOSES ONLY
REMS Program Live Training FOR TRAINING PURPOSES ONLY This educational module contains information on selected YESCARTA -associated adverse reactions, including cytokine release syndrome and neurologic
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Targeted Therapies/ Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationNew Drugs Update: Targeted Therapies
NEW DRUG UPDATES New Drugs Update: Targeted Therapies Megan Derba, Pharm.D. Supervising Pharmacist Hematology/Oncology Lafayette Family Cancer Institute Brewer, Maine November 2, 2018 Introduction Disclosures
More informationAntibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma
Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Steven I. Park, MD, 1* and Kristy L. Richards, PhD, MD 1 ABSTRACT Antibody-based immunotherapeutic agents have emerged as important
More informationCONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. PRC-498 IMBRUVICA
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationFAQs. Frequently Asked Questions. For more information, visit: Are there differences between ADCETRIS and traditional chemotherapy?
FAQs Frequently Asked Questions For more information, visit: www.adcetris.com For which conditions is ADCETRIS (brentuximab vedotin) used? Are there differences between ADCETRIS and traditional chemotherapy?
More informationMonitoring for peripheral neuropathy symptoms
Monitoring for peripheral neuropathy symptoms ADCETRIS (brentuximab vedotin) can cause a side effect called peripheral neuropathy (PN) that mostly involves numbness or tingling in the hands or feet (sensory
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationApproval based on the successful BFORE Phase 3 study conducted by Avillion under a collaborative development agreement with Pfizer
Avillion Announces US Approval of Pfizer s BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) Approval based on the successful BFORE Phase 3 study
More informationA Guide for Patients and Caregivers
DLBCL Starting KYMRIAH A Guide for Patients and Caregivers APPROVED USE WHAT IS KYMRIAH? KYMRIAH (tisagenlecleucel) is made from your own white blood cells and is a prescription cancer treatment used in
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.47 Subject: Revlimid Page: 1 of 6 Last Review Date: June 19, 2015 Revlimid Description Revlimid (lenalidomide)
More informationBC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine
BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine Protocol Code Tumour Group Contact Physician ULYOBBEND Lymphoma
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationKEYTRUDA Pembrolizumab
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KEYTRUDA Pembrolizumab powder for solution for infusion 50 mg solution for infusion 100 mg/4ml vial Antineoplastic agent, monoclonal antibody
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationImbruvica. Imbruvica (ibrutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.41 Subject: Imbruvica Page: 1 of 5 Last Review Date: September 15, 2017 Imbruvica Description Imbruvica
More informationKEYTRUDA Pembrolizumab
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KEYTRUDA Pembrolizumab powder for solution for infusion 50 mg solution for infusion 100 mg/4ml vial Antineoplastic agent, monoclonal antibody
More informationAxicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) second line
NIHR Innovation Observatory Evidence Briefing: August 2017 Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) second line NIHRIO
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More information